Aristotle University Of Thessaloniki (AUTH)
Μελέτη δεικτών αστροκυτταρικής ενεργοποίησης και νευρωνικής εκφύλισης στο εγκεφαλονωτιαίο υγρό των ασθενών με σκλήρυνση κατά πλάκας και συσχέτιση αυτών με κλινικές παραμέτρους της νόσου
Abstract
dc:descriptionTo date, there have been many studies into potential biomarkers for MS. Neurofilament light, tau protein and phospho tau participate in the cytoskeleton formation mainly of the axons, and neuroaxonal damage correlates with high protein levels in the cerebrospinal fluid. Astroglial response to neuronal injury has been assessed in previous studies with GFAP protein levels in the CSF. The aim of the study is to test neuronal (as NfL, tau and phospho tau) and astrocytic activation biomarkers (GFAP) and correlate with clinical characteristics of multiple sclerosis patients. This observational case–control study included patients with MS and controls with other neurological conditions. CSF levels of b-amyloid, tau, phospho tau, NfL and GFAP were determined using enzyme-linked immunosorbent assay. Clinical data (sex, age, duration of disease, type of disease, EDSS, previous disease modifying therapy, previous use of steroids and previous use of statins) of the patients were correlated with the measured proteins. Cognitive function was assessed in a sub-group of MS patients and was compared with NfL protein levels in the CSF. Follow up EDSS was measured 6-12 months after sampling in the group that underwent cognitive assessment. 87 MS patients (aged 41.1±11.96) enrolled in the study and 21 controls (aged 44.17 ±12.8). Increased levels of phospho tau181 were noted in the CSF of patients (p=0.03) in the progressive group with phospho tau median 40.4 (INQ 26-267), compared with phospho tau median 34.5 (INQ 22-89) in the relapsing group. EDSS did not correlate with the levels of the biomarkers in the CSF nor serum, but in a linear regression model an potential association was revealed between GFAP serum and EDSS change from baseline, with a negative association between GFAP serum levels and EDSS change (b=-2.95; 95%CI: from -4.58 to -1.32; p=0.003) with every increase in step in EDSS, adjusting for age. MS patients that had previous disease modifying treatment showed decreased levels in the phospho tau levels in the CSF, while previous steroid treatment within the last year or previous treatment with statins did not influence the levels of the proteins. EDSS score showed correlation with age (ρ=0.26, p=0.005) and duration of symptoms (p=0.011, ρ=0.24). Older patients in our sample had longer disease duration (p=0.00003, ρ=0.38). Phospho tau proved the most important biomarker to discriminate between relapsing and progressive forms on multiple sclerosis patients. In the subgroup of MS patients where cognition was assessed, NfL CSF levels were inversely correlated with the BICAMS composite z-scores in patients with progressive disease (ρ=-0.944, p=0.005). More studies are needed to validate the results, but our study provides preliminary evidence of CSF phopsho t as potential end point surrogate biomarker of progressive MS, GFAP serum as a potential biomarker of relapse and CSF NfL an indicator of cognitive decline in progressive MS. The development of end point biomarkers in clinical practice can offer a surrogate clinical tool for earlier diagnosis of progressive disease or cognitive decline and guide treatment options with a view to maximise clinical efficacy and minimise potential risks.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kalatha, Thaleia
- Καλαθά, Θάλεια
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47524